NasdaqGS:BEAT

Stock Analysis Report

Executive Summary

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide.

Snowflake

Fundamentals

Reasonable growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has BioTelemetry's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

7.9%

BEAT

5.8%

US Healthcare

1.8%

US Market


1 Year Return

-21.9%

BEAT

-6.5%

US Healthcare

7.3%

US Market

Return vs Industry: BEAT underperformed the US Healthcare industry which returned -6.5% over the past year.

Return vs Market: BEAT underperformed the US Market which returned 7.3% over the past year.


Shareholder returns

BEATIndustryMarket
7 Day7.9%5.8%1.8%
30 Day0.4%2.5%-0.7%
90 Day-7.4%-1.8%0.06%
1 Year-21.9%-21.9%-5.0%-6.5%9.7%7.3%
3 Year132.1%132.1%33.9%28.6%46.3%36.9%
5 Year476.3%476.3%65.6%55.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is BioTelemetry's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BioTelemetry undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: BEAT ($41.9) is trading below our estimate of fair value ($107.32)

Significantly Undervalued: BEAT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BEAT is poor value based on its PE Ratio (30.3x) compared to the Healthcare industry average (20.4x).

PE vs Market: BEAT is poor value based on its PE Ratio (30.3x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

Low PEG Ratio: BEAT is poor value based on its PEG Ratio (1.3x)


Price to Book Ratio

PB vs Industry: BEAT is overvalued based on its PB Ratio (4.1x) compared to the US Healthcare industry average (2.5x).


Next Steps

Future Growth

How is BioTelemetry forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

23.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BEAT's forecast earnings growth (23.9% per year) is above the savings rate (2.7%).

Earnings vs Market: BEAT's earnings (23.9% per year) are forecast to grow faster than the US market (14.6% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BEAT's revenue (12.1% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: BEAT's revenue (12.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if BEAT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has BioTelemetry performed over the past 5 years?

39.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BEAT has become profitable over the past 5 years, growing earnings by 39.9% per year.

Accelerating Growth: BEAT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BEAT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (5.3%).


Return on Equity

High ROE: BEAT's Return on Equity (13.4%) is considered low.


Return on Assets

ROA vs Industry: BEAT has a higher Return on Assets than the Healthcare industry average last year.


Return on Capital Employed

ROCE Improving: BEAT's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is BioTelemetry's financial position?


Financial Position Analysis

Short Term Liabilities: BEAT's short term assets ($130.0M) exceeds its short term liabilities ($59.3M)

Long Term Liabilities: BEAT's short term assets (130.0M) do not cover its long term liabilities (258.1M)


Debt to Equity History and Analysis

Debt Level: BEAT's debt to equity ratio (56.7%) is considered high

Reducing Debt: BEAT's debt to equity ratio has increased from 28.1% to 56.7% over the past 5 years.

Debt Coverage: BEAT's debt is well covered by operating cash flow (47.2%).

Interest Coverage: BEAT's interest payments on its debt are well covered by EBIT (7.2x coverage).


Balance Sheet

Inventory Level: BEAT has a low level of unsold assets or inventory.

Debt Coverage by Assets: BEAT's debt is not covered by short term assets (assets are 0.7x debt).


Next Steps

Dividend

What is BioTelemetry's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage1.6%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate BEAT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BEAT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if BEAT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BEAT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BEAT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of BioTelemetry's salary, the management and board of directors tenure and is there insider trading?

8.8yrs

Average management tenure


CEO

Joe Capper (55yo)

9.3yrs

Tenure

US$3,875,558

Compensation

Mr. Joseph H. Capper, also known as Joe, has been the Chief Executive Officer and President at BioTelemetry, Inc. formerly known as CardioNet, Inc. since June 2010. Mr. Capper served as the Chief Executive ...


CEO Compensation Analysis

Compensation vs. Market: Joe's total compensation ($USD3.88M) is about average for companies of similar size in the US market ($USD4.07M).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.


Management Age and Tenure

8.8yrs

Average Tenure

50yo

Average Age

Experienced Management: BEAT's management team is seasoned and experienced (8.8 years average tenure).


Board Age and Tenure

10.4yrs

Average Tenure

68yo

Average Age

Experienced Board: BEAT's board of directors are seasoned and experienced ( 10.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Peter Kowey

    Medical Director and Chairman of Medical Advisory Board

    • Tenure: 10.6yrs
  • Joe Capper (55yo)

    CEO, President & Director

    • Tenure: 9.3yrs
    • Compensation: US$3.88m
  • Peter Ferola (50yo)

    Senior VP

    • Tenure: 8.7yrs
    • Compensation: US$918.00k
  • Scott Satin

    President & General Manager of BioTel Research

    • Tenure: 0yrs
  • Andy Broadway (49yo)

    President of BioTel Heart

    • Tenure: 1.8yrs
    • Compensation: US$1.01m
  • Heather Getz (44yo)

    Executive VP & CFO

    • Tenure: 9.8yrs
    • Compensation: US$1.63m
  • Dan Wisniewski (55yo)

    Senior Vice President of Technical Operations

    • Tenure: 8.8yrs
    • Compensation: US$935.10k
  • Manish Wadhwa

    Chief Medical Officer

    • Tenure: 0.2yrs
  • Tim Raher

    Senior Vice President of Human Resources

    • Tenure: 2.3yrs

Board Members

  • Kirk Gorman (68yo)

    Independent Chairman

    • Tenure: 8yrs
    • Compensation: US$230.66k
  • Rebecca Rimel (68yo)

    Independent Director

    • Tenure: 10.4yrs
    • Compensation: US$205.03k
  • David Benditt (72yo)

    Member of Medical Advisory Board

    • Tenure: 0yrs
  • Peter Kowey

    Medical Director and Chairman of Medical Advisory Board

    • Tenure: 10.6yrs
  • Joe Frick (66yo)

    Independent Director

    • Tenure: 6yrs
    • Compensation: US$201.93k
  • Joe Capper (55yo)

    CEO, President & Director

    • Tenure: 9.3yrs
    • Compensation: US$3.88m
  • Robert Rubin (73yo)

    Independent Director

    • Tenure: 12.3yrs
    • Compensation: US$199.42k
  • Arthur Moss

    Member of Medical Advisory Board

    • Tenure: 10.6yrs
  • Kenneth Ellenbogen

    Member of Medical Advisory Board

    • Tenure: 10.6yrs
  • Tony Conti (70yo)

    Independent Director

    • Tenure: 7.4yrs
    • Compensation: US$203.16k

Company Information

BioTelemetry, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BioTelemetry, Inc.
  • Ticker: BEAT
  • Exchange: NasdaqGS
  • Founded: 1994
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: US$1.420b
  • Shares outstanding: 33.89m
  • Website: https://www.gobio.com

Number of Employees


Location

  • BioTelemetry, Inc.
  • 1000 Cedar Hollow Road
  • Suite 102
  • Malvern
  • Pennsylvania
  • 19355
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
C25DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2008
BEATNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 2008
0HNHLSE (London Stock Exchange)YesCommon StockGBUSDMar 2008

Biography

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manuf ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 00:07
End of Day Share Price2019/10/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.